WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H122625
CAS#: N/A
Description: XEN-D0101 is an experimental drug that was developed to treat atrial fibrillation, Xention, a biopharmaceutical company based in Cambridge, England, created XEN-D0101 along with other ion channel-modulating drugs. XEN-D0101 is a selective antagonist of the voltage-gated potassium channel Kv1.5. Atrial fibrillation is the main focus of Xention’s drug development, as it is the most common cardiac arrhythmia (irregular heart beat) seen in patients.
Hodoodo Cat#: H122625
Name: XEN-D0101
CAS#: N/A
Chemical Formula: C26H28N6O2S
Exact Mass: 488.20
Molecular Weight: 488.610
Elemental Analysis: C, 63.91; H, 5.78; N, 17.20; O, 6.55; S, 6.56
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: XEN-D0101; XEN D0101; XEND0101
IUPAC/Chemical Name: N-(2-hydroxyethyl)-1-(5-phenyl-4-((pyridin-2-ylmethyl)amino)thieno[2,3-d]pyrimidin-2-yl)piperidine-3-carboxamide
InChi Key: ZVUSKJPRMYQKKI-UHFFFAOYSA-N
InChi Code: InChI=1S/C26H28N6O2S/c33-14-12-28-24(34)19-9-6-13-32(16-19)26-30-23(29-15-20-10-4-5-11-27-20)22-21(17-35-25(22)31-26)18-7-2-1-3-8-18/h1-5,7-8,10-11,17,19,33H,6,9,12-16H2,(H,28,34)(H,29,30,31)
SMILES Code: OCCNC(C(C1)CCCN1C2=NC(NCC3=CC=CC=N3)=C(C(C4=CC=CC=C4)=CS5)C5=N2)=O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 488.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Ford J, Milnes J, Wettwer E, Christ T, Rogers M, Sutton K, Madge D, Virag L,
Jost N, Horvath Z, Matschke K, Varro A, Ravens U. Human electrophysiological and
pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur
inhibitor. J Cardiovasc Pharmacol. 2013 May;61(5):408-15. doi:
10.1097/FJC.0b013e31828780eb. PMID: 23364608.
2: Árpádffy-Lovas T, Mohammed ASA, Naveed M, Koncz I, Baláti B, Bitay M, Jost N,
Nagy N, Baczkó I, Virág L, Varró A. Species-dependent differences in the
inhibition of various potassium currents and in their effects on repolarization
in cardiac ventricular muscle. Can J Physiol Pharmacol. 2022 Sep
1;100(9):880-889. doi: 10.1139/cjpp-2022-0028. Epub 2022 Apr 20. PMID: 35442802.
3: Devalla HD, Schwach V, Ford JW, Milnes JT, El-Haou S, Jackson C, Gkatzis K,
Elliott DA, Chuva de Sousa Lopes SM, Mummery CL, Verkerk AO, Passier R. Atrial-
like cardiomyocytes from human pluripotent stem cells are a robust preclinical
model for assessing atrial-selective pharmacology. EMBO Mol Med. 2015
Apr;7(4):394-410. doi: 10.15252/emmm.201404757. PMID: 25700171; PMCID:
PMC4403042.
